Microchip Technology Inc
Change company Symbol lookup
Select an option...
MCHP Microchip Technology Inc
OSUR OraSure Technologies Inc
QUOT Quotient Technology Inc
DUK Duke Energy Corp
WAFD Washington Federal Inc
REML Credit Suisse X-Links Monthly Pay 2xLeveraged Mortgage REIT ETN
$NQG3010LMT Nasdaq Global Banks Large Mid Cap To
SRTS Sensus Healthcare Inc
LITB LightInTheBox Holding Co Ltd
MZA BlackRock MuniYield Arizona
Go

Information Technology : Semiconductors & Semiconductor Equipment | Large Cap Blend
Company profile

Microchip Technology Incorporated is engaged in developing, manufacturing and selling specialized semiconductor products used by its customers for a range of embedded control applications. The Company operates through two segments: semiconductor products and technology licensing. In the semiconductor products segment, the Company designs, develops, manufactures and markets microcontrollers, development tools and analog, interface, mixed signal and timing products. Its functional activities include sales, marketing, manufacturing, information technology, human resources, legal and finance. Its product portfolio comprises general purpose and specialized 8-bit, 16-bit, and 32-bit microcontrollers, a spectrum of linear, mixed-signal, power management, thermal management, radio frequency (RF), timing, safety, security, wired connectivity and wireless connectivity devices, as well as serial electrically erasable programmable read-only memories (EEPROMs) and serial flash memories.

Premarket

Last Trade
Delayed
$100.70
1.65 (1.67%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$99.05
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
156

10-day average volume:
1,871,532
156

Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences

4:56 pm ET September 15, 2020 (BusinessWire) Print

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune and neurodegenerative diseases, today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a corporate overview to virtual audiences this week at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference and at the Cantor Virtual Global Healthcare Conference.

Conferences Details
Event:                 H.C. Wainwright 22nd Annual Global Investment Conference (virtual) H.C. Wainwright 22nd Annual Global Investment Conference (virtual) H.C. Wainwright 22nd Annual Global Investment Conference (virtual)
Date:                  Wednesday, September 16th                                          Wednesday, September 16th                                          Wednesday, September 16th
Time:                  3:30 p.m. ET                                                       3:30 p.m. ET                                                       3:30 p.m. ET
                                                                                                     
Event:                 Cantor Virtual Global Healthcare Conference (virtual)              Cantor Virtual Global Healthcare Conference (virtual)              Cantor Virtual Global Healthcare Conference (virtual)
Date:                  Thursday, September 17th                                           Thursday, September 17th                                           Thursday, September 17th

Live webcasts of both presentations can be accessed by visiting the "Events and Presentations" tab of the investor section of the Novus website at http://ir.novustherapeutics.com/events-and-presentations/events. A replay of the webcasts will be archived for 30 days following the conference.

About Novus Therapeutics

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, Calif. For more information, please visit the company's website at www.novustherapeutics.com. Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements that involves substantial risks and uncertainties. Any statements about the company's future expectations, plans and prospects, including statements about its strategy, future operations, development of its product candidates, and other statements containing the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "predicts," "projects," "targets," "looks forward," "could," "may," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, although not all forward-looking statements include such identifying words. Forward-looking statements include, but are not limited to statements regarding: risks related to market conditions; expectations regarding the timing for the commencement of future clinical trials; expectations regarding the success of clinical trials; the rate and degree of market acceptance and clinical utility of the company's products; the company's estimates regarding expenses and cash runway; and the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company's actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the SEC, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200915006306/en/

SOURCE: Novus Therapeutics, Inc.

Amanda Sellers
asellers@vergescientific.com 
301.332.5574
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.